AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01929122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control Meals and Snacks
Study NCT01929122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cooked Navy Bean Powder Meals and Snacks
Study NCT01929122 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran Meals and Snacks
Study NCT04006171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C type natriuretic peptide
Description: Serum level of CNP in PCOS and healthy women
Study NCT02583217 — intervention group
Intervention type: DEVICE
Intervention: laryngeal mask
Study NCT04043741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
Study NCT04043741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sustain Pressure
Description: Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)
Study NCT03890666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol eMDPI DS
Description: Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)
Study NCT03890666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Description: Standard of care albuterol-administering rescue inhaler
Study NCT03339856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retina therapy
Description: The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery.
Study NCT02884232 — intervention group
Intervention type: PROCEDURE
Intervention: Nasofibroscopy
Study NCT04191993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Description: Surgical intervention designed to replace arthritic joint with artificial implant
Study NCT04191993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Surgical intervention designed to replace arthritic joint with artificial implant
Study NCT00050778 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
Study NCT00050778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Description: Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was >=100\*10\^6 cells per liter).
Study NCT00050778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Description: Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was >=100\*10\^6 cells per liter).
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Study NCT00131053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Study NCT00585598 — intervention group
Intervention type: OTHER
Intervention: replacing supralaryngeal airway with ET tube
Description: changing tube in trauma bay
Study NCT02935426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-butyl cyanoacrylate and 2-octyl cyanoacrylate
Description: used in cyanoacrylate group
Study NCT02935426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5-0 Polytetrafluoroethylene (PTFE) suture
Description: used in suture group
Study NCT03712371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
Study NCT03629314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational pamphlet arm
Description: Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
Study NCT02872506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti TNF
Description: Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
Study NCT02872506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ileocecal resection
Description: The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
Study NCT02568891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: multispecies probiotic
Study NCT02568891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matrix
Study NCT04583137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Layngeal direct fiberoptic examination transnasaly
Study NCT02791568 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound Scan
Description: The research exam is expected to take 30 minutes for blood flow assessments
Study NCT02791568 — intervention group
Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MR imaging will take approximately 30 minutes.
Study NCT02791568 — intervention group
Intervention type: DRUG
Intervention: Ferumoxytol
Description: A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
Study NCT04741126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually assisted cough technique
Description: Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
Study NCT00662467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + clopidogrel
Description: Dual therapy
Study NCT00662467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin + clopidogrel + warfarin
Description: Triple therapy
Study NCT03209128 — intervention group
Intervention type: RADIATION
Intervention: Irradiation prophyllactique cérébrale
Description: Irradiation prophyllactique cérébrale
Study NCT00835211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: 4 x 0.2 mg, single-dose fasting
Study NCT00835211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP® 0.2 mg Tablets
Description: 4 x 0.2 mg, single-dose fasting
Study NCT00749112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab, Rituximab
Description: Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
Study NCT04529486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
Study NCT03614052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride 0.4 milligrams
Description: Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
Study NCT03614052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
Study NCT03347370 — intervention group
Intervention type: DRUG
Intervention: SC Peginterferon beta-1a
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
Study NCT03347370 — intervention group
Intervention type: DRUG
Intervention: SC interferon beta-1a
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
Study NCT03347370 — intervention group
Intervention type: DRUG
Intervention: SC interferon beta-1b
Description: All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
Study NCT03180619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet administered orally once daily
Study NCT03635450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of hCT-MSC
Description: Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
Study NCT01736761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir, Ritonavir and Rilpivirine
Study NCT04381039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: 3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
Study NCT00892840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
Study NCT00892840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once daily, 14 days
Study NCT01809093 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: 3-4 tablespoons of blood will be drawn, one time.
Study NCT00470834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: 0.5mg dutasteride (Investigation Product)
Study NCT00470834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: making placebo
Study NCT00470834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: 50 mg Casodex or generic equivalent
Study NCT00470834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bicalutamide
Description: 50 mg Casodex or generic equivalent
Study NCT03662581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Group Program
Description: The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg placebo to match
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 mg placebo to match
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg placebo to match
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 5 mg placebo to match
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin 5 mg
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
Study NCT03608358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
Study NCT03284892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC program
Description: A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
Study NCT00305461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Effect of Ciclesonide on Quality of Life
Study NCT02765009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diuretics
Description: Used to reduce fluid overload as evidenced by weight gain
Study NCT02765009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin
Description: Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
Study NCT02765009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid restriction
Description: Used to reduce fluid overload
Study NCT02765009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal replacement
Description: Used to reduce fluid overload in patients with renal replacement
Study NCT00443963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: PPI compared to H2RA
Study NCT04585061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
Study NCT04585061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality device (Harga Miniso Vr Glass 3d terbaru)
Description: Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized
Study NCT04585061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
Study NCT04600271 — intervention group
Intervention type: DRUG
Intervention: Crystalloid Solutions
Description: exposure
Study NCT04600271 — intervention group
Intervention type: DRUG
Intervention: Colloid Blood Volume Expanders
Description: exposure
Study NCT04600271 — intervention group
Intervention type: OTHER
Intervention: blood replacement
Description: exposure
Study NCT04600271 — intervention group
Intervention type: DRUG
Intervention: Diuretic
Description: exposure
Study NCT04600271 — intervention group
Intervention type: DRUG
Intervention: noradrenaline
Description: exposure
Study NCT04600271 — intervention group
Intervention type: DRUG
Intervention: Non-Steroidal Anti-Inflammatory Analgesics
Description: exposure
Study NCT03761862 — intervention group
Intervention type: PROCEDURE
Intervention: Neural Therapy
Description: Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
Study NCT03515317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LoRETA Z-score NF
Description: LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
Study NCT05774860 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention